logo-loader
viewSynthis

Synthis looking at a different and unique way of treating oncology patients

Dori Karyat, Founder and CEO and founder, Synthis is an early stage, New York-based biotech company, sat down with Christine Corrado at the BioCeo conference In New York, to share news about their novel immuno-oncology therapeutic way of treating metastatic melanoma patients. Karyat talks about how the company started and where they are in their development. 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CB Therapeutics achieved the successful biosynthesis of psilocybin, psilocin

CB Therapeutics CEO Sher Butt joined Steve Darling with news the company has recently hit another milestone finding, in early testing, the analysis of raw analytical samples has shown the biosynthetic process of psilocybin, psilocin and related tryptamine-based compounds to be significantly more...

18 minutes ago

2 min read